Danaher Co. (DHR) Chairman Acquires $248,482.00 in Stock
Danaher Co. (NYSE:DHR) Chairman Mitchell P. Rales purchased 1,900 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were purchased at an average price of $130.78 per share, for a total transaction of $248,482.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Shares of DHR stock opened at $130.75 on Thursday. Danaher Co. has a 12-month low of $94.59 and a 12-month high of $134.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.74 and a current ratio of 2.18. The company has a market capitalization of $92.68 billion, a P/E ratio of 28.93, a P/E/G ratio of 2.50 and a beta of 1.02.
Danaher (NYSE:DHR) last issued its earnings results on Thursday, April 18th. The conglomerate reported $1.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.06. Danaher had a net margin of 12.04% and a return on equity of 11.61%. The company had revenue of $4.88 billion for the quarter, compared to analysts’ expectations of $4.80 billion. During the same quarter last year, the company posted $0.99 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. As a group, equities analysts predict that Danaher Co. will post 4.77 EPS for the current year.
DHR has been the topic of a number of recent analyst reports. Janney Montgomery Scott increased their price target on shares of Danaher from $136.00 to $174.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Jefferies Financial Group increased their price target on shares of Danaher to $140.00 and gave the company a “buy” rating in a report on Tuesday, February 26th. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $140.00 price target on shares of Danaher in a report on Monday, March 4th. Zacks Investment Research upgraded shares of Danaher from a “sell” rating to a “hold” rating in a report on Monday, May 6th. Finally, Needham & Company LLC restated a “buy” rating and issued a $138.00 target price (up previously from $114.00) on shares of Danaher in a report on Thursday, February 28th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Danaher presently has a consensus rating of “Buy” and an average target price of $131.75.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in DHR. Laurel Wealth Advisors LLC bought a new position in Danaher in the fourth quarter worth approximately $27,000. CX Institutional raised its position in Danaher by 188.7% in the first quarter. CX Institutional now owns 205 shares of the conglomerate’s stock worth $27,000 after acquiring an additional 134 shares during the period. Hanson McClain Inc. raised its position in Danaher by 852.9% in the fourth quarter. Hanson McClain Inc. now owns 324 shares of the conglomerate’s stock worth $33,000 after acquiring an additional 290 shares during the period. Executive Wealth Management LLC bought a new position in Danaher in the fourth quarter worth approximately $39,000. Finally, Ruggie Capital Group bought a new position in Danaher in the fourth quarter worth approximately $40,000. Institutional investors and hedge funds own 76.98% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Featured Article: Is a Roth IRA right for you?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.